ArticleParasites & vectors2026
Evaluation of the potential therapeutic efficacy of Cerastes cerastes venom in acute experimental toxoplasmosis.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe control of toxoplasmosis relies on conventional chemotherapeutics, which have hitherto unresolved concerns.
methodsSwiss albino mice were intraperitoneally (IP) infected with 5 × 10
resultsCCV induced an insignificant reduction in mortality rate (MR) and a significant increase in survival time of mice. A statistically significant decrease in the mean peritoneal parasite burden with 89.8% and 90.8% reduction (%R) was observed in both IC and IS-treated subgroups compared with their controls, respectively. This reduction was consistent with 88% and 86% decrease in liver parasite load, respectively, and obvious ultrastructural alterations in treated tachyzoites. Concerning the infectivity study, the percent reduction was 78.8% and 85.5% in the peritoneal fluid and 71.1% and 60.4% in the liver tissues of IC and IS subgroups, respectively. The biochemical safety of the used dose and its high antioxidant activity were verified.
conclusionsThus, one-fourth LD50 of CCV can be considered a promising, effective natural alternative to standard chemotherapy for acute toxoplasmosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.